Abstracts tagged "Systemic Inflammatory"

Abstract Number: 122 • 2020 Pediatric Rheumatology Symposium
Systemic Inflammation and Cognitive Dysfunction in jSLE Patients
Sara Ganhão ¹, Mariana Rodrigues², Beatriz Silva ¹, Francisca Aguiar ¹, Margarida Figueiredo-Braga ¹ and Iva Brito ¹, ¹Centro Hospitalar de São João, Oporto, Portugal, ²Porto, Portugal
Background/Purpose: Neurocognitive dysfunction (NCD) is one of the most commonly reported neuropsychiatric symptoms in patients with juvenile systemic lupus erythematosus (SLE), even without overt CNS…
Abstract Number: 992 • 2018 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses Systemic Inflammation By Inhibiting IL-6-Induced STAT3 Activation in Cultured Hepatocytes and in Liver Tissue of Adjuvant-Induced Arthritis (AIA) Rats
Anil K. Singh¹, Sabrina Fechtner², Dorothy Wang², Mukesh Chourasia³ and Salahuddin Ahmed^2,4, ¹Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Pharmacoinformatics,, National lnstitute of Pharmaceutical Education and Research, Hajipur,, India, ⁴Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: In rheumatoid arthritis (RA), the pro-inflammatory cytokine interleukin-6 (IL-6) induces systemic inflammation by activating hepatocytes through IL-6 receptor (IL-6R)- mediated JAK/STAT3 signaling pathway. The…
Abstract Number: 2230 • 2017 ACR/ARHP Annual Meeting
Use of Prescription Opioids Among Patients with Systemic Inflammatory Diseases (SID) Versus Patients with Hypertension but No Sid
Sarah Chen¹, Candace H. Feldman², Gregory Brill³, Yvonne C. Lee⁴, Rishi J. Desai⁵ and Seoyoung C. Kim⁶, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham & Women's Hospital, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, ⁴Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁶Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Opioid prescribing in the U.S. has increased at an alarming rate amid uncertainty over effectiveness and rising concerns over safety of this practice. Patients…
Abstract Number: 84 • 2017 ACR/ARHP Annual Meeting
Physiological Autoantibodies Against the Endthelin Receptor Type-a Are Critically Involved in the Homeostasis of Immune Cells
Otávio Cabral-Marques¹, Harald Heidecke², Frank Petersen³, Xinhua Yu⁴ and Gabriela Riemekasten⁵, ¹Department of Rheumatology, Vasculitis Center UKSH, University of Lübeck, Luebeck, Germany, ²CellTrend GmbH Luckenwalde, Luckenwalde, Germany, ³Research Centre Borstel, Borstel, Germany, ⁴Lung Centre Borstel, a Leibniz institute, Borstel, Germany, ⁵Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany
Background/Purpose: G protein-coupled receptors (GPCRs) are a family of integral membrane proteins mediating cell trafficking and cellular homeostasis. In the last decades, several functional autoantibodies…
Abstract Number: 2197 • 2017 ACR/ARHP Annual Meeting
Systemic Inflammation and Physical Function in Knee Osteoarthritis
Devyani Misra¹, Carrie Brown², Roger A. Fielding³, Tuhina Neogi⁴, Michael C. Nevitt⁵, Cora E. Lewis⁶, James Torner⁷ and David T. Felson⁴, ¹Medicine, Section of, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, ⁴Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ⁵Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁶University of Alabama Birmingham, Birmingham, AL, ⁷University of Iowa, Iowa City, IA
Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation and disability in older adults. But why some knee OA patients develop functional limitation…
Abstract Number: 172 • 2016 ACR/ARHP Annual Meeting
S100A8/A9 Produced during Experimental Osteoarthritis Induces a Systemic Decrease in BM Monocytes and Increases Ly6C High Monocytes Locally in the Joint
Niels Cremers, Edwin Geven, Arjen Blom, Annet Sloetjes, Irene Di Ceglie, Stephanie van Dalen, Giuliana Ascone, Martijn van den Bosch and Peter van Lent, Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: In response to pro-inflammatory cytokines released locally during osteoarthritis (OA), such as the alarmins S100A8/A9, monocytes can be recruited from the bone marrow (BM)…
Abstract Number: 1492 • 2016 ACR/ARHP Annual Meeting
Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis: A Population-Based Study
Jeffrey Curtis¹, Fenglong Xie², Lang Chen² and Huifeng Yun³, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Serious infection events (SIE) and myocardial infarction (MI) are among the most concerning adverse events that occur in rheumatoid arthritis (RA) patients. The role…
Abstract Number: 2843 • 2016 ACR/ARHP Annual Meeting
Prevalence of Anti-DFS70 Antibodies in Patients with and without Systemic Autoimmune Rheumatic Diseases
Ora Shovman¹, Boris Gilburd², Chen Chayat³, Howard Amital^1,4, Abdulla Watad⁵, Adi Guy⁵, Chelsea Bentow⁶, Michael Mahler⁶ and Yehuda Shoenfeld^1,4, ¹Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ²Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat-Gan, Israel, ³Zabludowitz Center for Autoimmune Diseases Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ⁴Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, Tel-Aviv, Israel, ⁵Internal Medicine B, Internal Medicine B, Sheba Medical Center, 52621, Tel Hashomer, Israel, Ramat Gan, Israel, ⁶Research and Development, Inova Diagnostics, San Diego, CA
Background/Purpose: Autoantibodies to the dense fine speckled 70 (DFS70) antigen are common among ANA (dense fine speckled pattern) positive healthy individuals and consequently reduce the…
Abstract Number: 3082 • 2016 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome Is Identified By Coagulopathy, Hyperferritinemia, Fever, and Cytopenia in Hospitalized Patients, Resulting in Poor Outcome
Bita Shakoory¹, Negin Mohtasham², Matthew Mullen³, Richard Amdur⁴ and W. Winn Chatham⁵, ¹None, MCLEAN, VA, ²Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ³Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Surgery, George Washington University, Washington, DC, ⁵Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Macrophage activation syndrome (MAS) constitutes over 5% of multi-organ dysfunction syndrome in adults, leading to 60-70% mortality without early treatment. H-Score, the only validated…
Abstract Number: 622 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes
Frederick B Vivino¹, Gary Foulks², S. Lance Forstot³, Peter Donshik⁴, Joseph Forstot⁵, Michael Goldstein⁶, Michael Lemp⁷, J. Daniel Nelson^8,9, Kelly K. Nichols^10,11, Stephen C. Pflugfelder¹², Jason Tanzer¹³, Penny Asbell¹⁴, Deborah S. Jacobs^15,16, Katherine M Hammitt¹⁷ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹University of Pennsylvania, Philadelphia, PA, ²Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY, ³Corneal Consultants of Colorado, Littleton, CO, ⁴Department of Ophthalmology, University of Connecticut Health Center, Farmington, CT, ⁵Rheumatology Associates of South Florida, Boca Raton, FL, ⁶New England Eye Center, Tufts Medical Center, Boston, MA, ⁷Department of Ophthalmology, Georgetown University, Washington, DC, ⁸Ophthalmology, HealthPartners Specialty Center, St. Paul, MN, ⁹Dept. of Ophthalmology, University of Minnesota, St. Paul, MN, ¹⁰School of Optometry, The University of Alabama at Birmingham, Birmingham, AL, ¹¹College of Optometry, (formerly) University of Houston, Houston, TX, ¹²Ocular Surface Center, Baylor College of Medicine, Cullen Eye Institute, Houston, TX, ¹³Department of Oral Health and Diagnostic Sciences, University of Connecticut School of Dental Medicine, Farmington, CT, ¹⁴Dept of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, NY, ¹⁵Boston Foundation for Sight, Needham, MA, ¹⁶Cornea and External Diseases, Massachusetts Eye and Ear, Boston, MA, ¹⁷Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: Dry eyes can compromise quality of life in Sjogren’s Syndrome (SS) and is often one of the most troublesome symptoms. Clinical practice guidelines were…
Abstract Number: 625 • 2015 ACR/ARHP Annual Meeting
Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease
Frederick B Vivino¹, Steven E. Carsons², Ann Parke³, Nancy Carteron⁴, Vidya Sankar⁵, Richard Brasington⁶, Robert Fox⁷, William Ehlers³, Michael Brennan⁸, Robert Hal Scofield⁹, Katherine M Hammitt¹⁰ and Sjogren's Syndrome Foundation Clinical Practice Guidelines Committee, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, ³University of Connecticut, Farmington, CT, ⁴University of California, San Francisco, CA, ⁵Univeristy of Texas, San Antonio, TX, ⁶Washington University, St Louis, MO, ⁷Rheumatology Clinic, La Jolla, CA, ⁸Carolinas Medical Center, Charlotte, NC, ⁹Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation; Department of Medicine, University of Oklahoma Health Sciences Center; US Department of Veterans Affairs Medical Center, Oklahoma City, OK, ¹⁰Vice President of Medical and Scientific Affairs, Sjögren's Syndrome Foundation, Bethesda, MD
Background/Purpose: There are currently no FDA approved immunomodulating agents available for treatment of the extraglandular manifestations of Sjogren’s (SS). Clinical practice guidelines were developed for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].